Cassava Sciences Announces Agreement With FDA n Special Protocol Assessments For Its Phase 3 Studies Of Simufilam For Treatment Of Alzheimer’s Disease
Cassava Sciences, Inc. (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol